These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29096837)

  • 1. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    Bergmark BA; Marston NA; Prohaska TA; Alexander VJ; Zimerman A; Moura FA; Murphy SA; Goodrich EL; Zhang S; Gaudet D; Karwatowska-Prokopczuk E; Tsimikas S; Giugliano RP; Sabatine MS;
    N Engl J Med; 2024 May; 390(19):1770-1780. PubMed ID: 38587249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volanesorsen: First Global Approval.
    Paik J; Duggan S
    Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
    Gaudet D; Alexander VJ; Baker BF; Brisson D; Tremblay K; Singleton W; Geary RS; Hughes SG; Viney NJ; Graham MJ; Crooke RM; Witztum JL; Brunzell JD; Kastelein JJ
    N Engl J Med; 2015 Jul; 373(5):438-47. PubMed ID: 26222559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials.
    Fogacci F; Norata GD; Toth PP; Arca M; Cicero AFG
    Curr Atheroscler Rep; 2020 May; 22(5):18. PubMed ID: 32458077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
    Warden BA; Duell PB
    Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olezarsen, a liver-directed
    Hooper AJ; Bell DA; Burnett JR
    Expert Opin Pharmacother; 2024 Oct; 25(14):1861-1866. PubMed ID: 39305266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
    N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
    Kohan AB
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.
    Calcaterra I; Lupoli R; Di Minno A; Di Minno MND
    Eur J Clin Invest; 2022 Nov; 52(11):e13841. PubMed ID: 35851450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglyceride-Rich Lipoproteins.
    Kockx M; Kritharides L
    Cardiol Clin; 2018 May; 36(2):265-275. PubMed ID: 29609756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
    Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
    Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ApoCIII: the next PCSK9?
    Bernelot Moens SJ; van Capelleveen JC; Stroes ES
    Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.